LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
LNSR
LENSAR, Inc.
There isn't enough reported data to score LNSR yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LNSR Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Strong |
LNSR's revenue and balance sheet are currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LNSR PE Valuation
LNSR has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over LNSR on the outlook, with more favorable earnings and profitability expectations.
LNSR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect LNSR's losses to grow, with revenue growing.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the stronger earnings trend. Trailing diluted EPS is up 51% for LLY versus LNSR down 205%.
LNSR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | -$2.87 | -$0.14 |
| Q3 2025 | -$4.40 | -$2.96 |
| Q2 2025 | -$4.22 | -$2.68 |
| Q1 2025 | -$4.86 | -$3.30 |
| Q4 2024 | -$2.73 | -$0.96 |
| Q3 2024 | -$1.44 | +$0.23 |
| Q2 2024 | -$1.54 | +$0.29 |
| Q1 2024 | -$1.56 | +$0.13 |
LNSR lost $2.87 per share over the past year, about the same as its loss the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over LNSR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LNSR on profitability, with a higher operating margin.
LNSR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $14.1M | -1.3% |
| Q2 2026 | $16.5M | +18% |
| Q1 2026 | $13.4M | -5.2% |
| Q4 2025 | $16M | -4.2% |
| Q3 2025 | $14.3M | +5.7% |
| Q2 2025 | $13.9M | +10% |
| Q1 2025 | $14.2M | +34% |
| Q4 2024 | $16.7M | +38% |
LNSR's revenue fell from its 2024 peak and has held roughly level since: $14M last quarter, down 1.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -10% | +43 points |
| Q2 2026 | 13% | +58 points |
| Q1 2026 | 17% | +58 points |
| Q4 2025 | -31% | -23 points |
| Q3 2025 | -53% | -44 points |
| Q2 2025 | -45% | -3.3 points |
| Q1 2025 | -41% | -14 points |
| Q4 2024 | -7.7% | +17 points |
LNSR's operating margin was −10% last quarter, up 43 points from the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with LNSR at up 22%.
LNSR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$978K | +$2.5M |
| Q4 2025 | $618K | -83% |
| Q3 2025 | -$3.5M | -212% |
| Q2 2025 | -$5.1M | -$1.2M |
| Q1 2025 | -$6.9M | -$1.6M |
| Q4 2024 | $3.7M | +$4.2M |
| Q3 2024 | $3.1M | +$3.5M |
| Q2 2024 | -$3.9M | -$1.6M |
LNSR has burned cash in almost every quarter: −$9M over the past year, against −$4M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LNSR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LNSR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -46% | -10.6M shares |
| 1 year | +3.9% | +461K shares |
| 3 years | +15% | +1.6M shares |
| 5 years | +33% | +3.1M shares |
| Available history | +17% | +1.8M shares |
LNSR has 12M diluted shares, up 3.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LNSR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.3x | Net Cash |
LNSR has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LNSR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.2 | Neutral |
| Stochastic | 12.6 | Oversold |
LNSR's weekly RSI is 34 (neutral) and its Stochastic is 13 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LNSR PE vs Healthcare Sector
LNSR has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LNSR on trend strength, trading above more of its moving averages.
LNSR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.99 | 22% below |
| 20 week MA | $6.56 | 28% below |
| 50 week MA | $7.88 | 40% below |
| 100 week MA | $10.0 | 53% below |
| 200 week MA | $6.92 | 32% below |
LNSR is in a downtrend: it's below all five of its weekly moving averages, and 32% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over LNSR on returns for 2026, with the stronger performance.
LNSR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.00 | $6.86 | -24% |
| 2021 | $6.86 | $6.00 | -13% |
| 2022 | $6.00 | $2.77 | -54% |
| 2023 | $2.77 | $3.51 | +27% |
| 2024 | $3.51 | $8.38 | +139% |
| 2025 | $8.38 | $12.0 | +43% |
| 2026 YTD | $12.0 | $4.70 | -61% |
LNSR's yearly returns have swung widely, from +139% in 2024 to −54% in 2022. It's down 61% so far in 2026.